436 related articles for article (PubMed ID: 19845851)
21. AZD6244 (ARRY-142886) enhances the antitumor activity of rapamycin in mouse models of human hepatocellular carcinoma.
Huynh H
Cancer; 2010 Mar; 116(5):1315-25. PubMed ID: 20101735
[TBL] [Abstract][Full Text] [Related]
22. Inhibition of mTOR in combination with doxorubicin in an experimental model of hepatocellular carcinoma.
Piguet AC; Semela D; Keogh A; Wilkens L; Stroka D; Stoupis C; St-Pierre MV; Dufour JF
J Hepatol; 2008 Jul; 49(1):78-87. PubMed ID: 18486258
[TBL] [Abstract][Full Text] [Related]
23. mTOR and P70 S6 kinase expression in primary liver neoplasms.
Sahin F; Kannangai R; Adegbola O; Wang J; Su G; Torbenson M
Clin Cancer Res; 2004 Dec; 10(24):8421-5. PubMed ID: 15623621
[TBL] [Abstract][Full Text] [Related]
24. A hepatocellular carcinoma-specific adenovirus variant, CV890, eliminates distant human liver tumors in combination with doxorubicin.
Li Y; Yu DC; Chen Y; Amin P; Zhang H; Nguyen N; Henderson DR
Cancer Res; 2001 Sep; 61(17):6428-36. PubMed ID: 11522637
[TBL] [Abstract][Full Text] [Related]
25. mTOR inhibitor rapamycin alone or combined with cisplatin inhibits growth of esophageal squamous cell carcinoma in nude mice.
Hou G; Zhang Q; Wang L; Liu M; Wang J; Xue L
Cancer Lett; 2010 Apr; 290(2):248-54. PubMed ID: 19853373
[TBL] [Abstract][Full Text] [Related]
26. Mammalian target of rapamycin, a molecular target in squamous cell carcinomas of the head and neck.
Amornphimoltham P; Patel V; Sodhi A; Nikitakis NG; Sauk JJ; Sausville EA; Molinolo AA; Gutkind JS
Cancer Res; 2005 Nov; 65(21):9953-61. PubMed ID: 16267020
[TBL] [Abstract][Full Text] [Related]
27. Serotonin promotes tumor growth in human hepatocellular cancer.
Soll C; Jang JH; Riener MO; Moritz W; Wild PJ; Graf R; Clavien PA
Hepatology; 2010 Apr; 51(4):1244-54. PubMed ID: 20099302
[TBL] [Abstract][Full Text] [Related]
28. The dual targeting of insulin and insulin-like growth factor 1 receptor enhances the mTOR inhibitor-mediated antitumor efficacy in hepatocellular carcinoma.
Pivonello C; Negri M; De Martino MC; Napolitano M; de Angelis C; Provvisiero DP; Cuomo G; Auriemma RS; Simeoli C; Izzo F; Colao A; Hofland LJ; Pivonello R
Oncotarget; 2016 Mar; 7(9):9718-31. PubMed ID: 26756219
[TBL] [Abstract][Full Text] [Related]
29. Mammalian target of rapamycin regulates expression of β-catenin in hepatocellular carcinoma.
Feng Z; Fan X; Jiao Y; Ban K
Hum Pathol; 2011 May; 42(5):659-68. PubMed ID: 21239045
[TBL] [Abstract][Full Text] [Related]
30. MAP kinase-interacting kinase 1 regulates SMAD2-dependent TGF-β signaling pathway in human glioblastoma.
Grzmil M; Morin P; Lino MM; Merlo A; Frank S; Wang Y; Moncayo G; Hemmings BA
Cancer Res; 2011 Mar; 71(6):2392-402. PubMed ID: 21406405
[TBL] [Abstract][Full Text] [Related]
31. Synergistic interactions between sorafenib and bortezomib in hepatocellular carcinoma involve PP2A-dependent Akt inactivation.
Chen KF; Yu HC; Liu TH; Lee SS; Chen PJ; Cheng AL
J Hepatol; 2010 Jan; 52(1):88-95. PubMed ID: 19913321
[TBL] [Abstract][Full Text] [Related]
32. V-AKT murine thymoma viral oncogene homolog/mammalian target of rapamycin activation induces a module of metabolic changes contributing to growth in insulin-induced hepatocarcinogenesis.
Evert M; Calvisi DF; Evert K; De Murtas V; Gasparetti G; Mattu S; Destefanis G; Ladu S; Zimmermann A; Delogu S; Thiel S; Thiele A; Ribback S; Dombrowski F
Hepatology; 2012 May; 55(5):1473-84. PubMed ID: 22271091
[TBL] [Abstract][Full Text] [Related]
33. IPD-196, a novel phosphatidylinositol 3-kinase inhibitor with potent anticancer activity against hepatocellular carcinoma.
Lee JH; Lee H; Yun SM; Jung KH; Jeong Y; Yan HH; Hong S; Hong SS
Cancer Lett; 2013 Feb; 329(1):99-108. PubMed ID: 23142281
[TBL] [Abstract][Full Text] [Related]
34. Antroquinonol displays anticancer potential against human hepatocellular carcinoma cells: a crucial role of AMPK and mTOR pathways.
Chiang PC; Lin SC; Pan SL; Kuo CH; Tsai IL; Kuo MT; Wen WC; Chen P; Guh JH
Biochem Pharmacol; 2010 Jan; 79(2):162-71. PubMed ID: 19723512
[TBL] [Abstract][Full Text] [Related]
35. Interleukin-6-stimulated progranulin expression contributes to the malignancy of hepatocellular carcinoma cells by activating mTOR signaling.
Liu F; Zhang W; Yang F; Feng T; Zhou M; Yu Y; Yu X; Zhao W; Yi F; Tang W; Lu Y
Sci Rep; 2016 Feb; 6():21260. PubMed ID: 26879559
[TBL] [Abstract][Full Text] [Related]
36. [Inhibition of growth and metastasis of hepatocellular carcinoma by rapamycin: experiment with mice].
Wang Z; Fan J; Zhou J; Wu ZQ; Qiu SJ; Yu Y; Huang XW; Tang ZY
Zhonghua Yi Xue Za Zhi; 2006 Jun; 86(24):1666-70. PubMed ID: 16854316
[TBL] [Abstract][Full Text] [Related]
37. Dasatinib synergises with irinotecan to suppress hepatocellular carcinoma via inhibiting the protein synthesis of PLK1.
Xu L; Zhu Y; Shao J; Chen M; Yan H; Li G; Zhu Y; Xu Z; Yang B; Luo P; He Q
Br J Cancer; 2017 Apr; 116(8):1027-1036. PubMed ID: 28267710
[TBL] [Abstract][Full Text] [Related]
38. Alterations of hypoxia-induced factor signaling pathway due to mammalian target of rapamycin (mTOR) suppression in ovarian clear cell adenocarcinoma: in vivo and in vitro explorations for clinical trial.
Hirasawa T; Miyazawa M; Yasuda M; Shida M; Ikeda M; Kajiwara H; Matsui N; Fujita M; Muramatsu T; Mikami M
Int J Gynecol Cancer; 2013 Sep; 23(7):1210-8. PubMed ID: 23899586
[TBL] [Abstract][Full Text] [Related]
39. The rapamycin-sensitive signal transduction pathway as a target for cancer therapy.
Hidalgo M; Rowinsky EK
Oncogene; 2000 Dec; 19(56):6680-6. PubMed ID: 11426655
[TBL] [Abstract][Full Text] [Related]
40. Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway.
Wang SS; Chen YH; Chen N; Wang LJ; Chen DX; Weng HL; Dooley S; Ding HG
Cell Death Dis; 2017 Mar; 8(3):e2688. PubMed ID: 28333142
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]